Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMC-AMI
- Development stage
- Unknown
- Lead developer
- TotipotentRX
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
BMC-AMI (also known as AMIRST) is an autologous bone marrow mononuclear cell (BMC) therapy developed by Beijing Boya Research Institution (Boyalife Group) in collaboration with Cesca Therapeutics (formerly ThermoGenesis and TotipotentRX). The therapy is prepared at the point-of-care using the SurgWerks-AMI and VXP system, which isolates and concentrates stem and progenitor cells (including hematopoietic stem cells, mesenchymal stem cells, and endothelial progenitor cells) from the patient's own bone marrow without the use of density gradient media. BMC-AMI is designed to support myocardial repair, reduce adverse remodeling, and improve cardiac function through regenerative and paracrine effects in patients who have suffered an acute myocardial infarction (AMI) with low left ventricular ejection fraction (LVEF). It is currently in Phase 1/2 clinical development.
- Other names
- AMIRSTAMIRST IAMIRST IIAutologous Bone Marrow Mononuclear Cell TherapyAutologous bone marrow mononuclear cells for AMISurgWerks-AMI
Beyond the preview
Go deeper on BMC-AMI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMC-AMI.